shutterstock_2174132583_fizkes
fizkes / Shutterstock.com
29 June 2023Big PharmaLiz Hockley

US appeals court upholds decision on wrinkle treatment

Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
20 July 2021   The Patent Trial and Appeal Board has ruled that a Medytox patent for its wrinkle treatment should not have been granted.
Americas
30 January 2020   The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

More on this story

Big Pharma
20 July 2021   The Patent Trial and Appeal Board has ruled that a Medytox patent for its wrinkle treatment should not have been granted.
Americas
30 January 2020   The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

More on this story

Big Pharma
20 July 2021   The Patent Trial and Appeal Board has ruled that a Medytox patent for its wrinkle treatment should not have been granted.
Americas
30 January 2020   The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.